94 related articles for article (PubMed ID: 22136887)
1. Nonlinear compartmental model of 18F-choline.
Tavola F; Janzen T; Giussani A; Facchinetti D; Veronese I; Uusijärvi-Lizana H; Mattsson S; Hoeschen C; Cantone MC
Nucl Med Biol; 2012 Feb; 39(2):261-8. PubMed ID: 22136887
[TBL] [Abstract][Full Text] [Related]
2. A compartmental model for biokinetics and dosimetry of 18F-choline in prostate cancer patients.
Giussani A; Janzen T; Uusijärvi-Lizana H; Tavola F; Zankl M; Sydoff M; Bjartell A; Leide-Svegborn S; Söderberg M; Mattsson S; Hoeschen C; Cantone MC
J Nucl Med; 2012 Jun; 53(6):985-93. PubMed ID: 22570328
[TBL] [Abstract][Full Text] [Related]
3. Biokinetics of 18F-choline studied in four prostate cancer patients.
Uusijärvi H; Nilsson LE; Bjartell A; Mattsson S
Radiat Prot Dosimetry; 2010; 139(1-3):240-4. PubMed ID: 20150231
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC).
Henriksen G; Herz M; Hauser A; Schwaiger M; Wester HJ
Nucl Med Biol; 2004 Oct; 31(7):851-8. PubMed ID: 15464386
[TBL] [Abstract][Full Text] [Related]
5. Quantification of 18F-fluorocholine kinetics in patients with prostate cancer.
Verwer EE; Oprea-Lager DE; van den Eertwegh AJ; van Moorselaar RJ; Windhorst AD; Schwarte LA; Hendrikse NH; Schuit RC; Hoekstra OS; Lammertsma AA; Boellaard R
J Nucl Med; 2015 Mar; 56(3):365-71. PubMed ID: 25678491
[TBL] [Abstract][Full Text] [Related]
6. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
[TBL] [Abstract][Full Text] [Related]
7. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
8. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer.
Zanzonico PB; Finn R; Pentlow KS; Erdi Y; Beattie B; Akhurst T; Squire O; Morris M; Scher H; McCarthy T; Welch M; Larson SM; Humm JL
J Nucl Med; 2004 Nov; 45(11):1966-71. PubMed ID: 15534070
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
DeGrado TR; Coleman RE; Wang S; Baldwin SW; Orr MD; Robertson CN; Polascik TJ; Price DT
Cancer Res; 2001 Jan; 61(1):110-7. PubMed ID: 11196147
[TBL] [Abstract][Full Text] [Related]
10. 18F-choline PET/CT for initial staging of advanced prostate cancer.
Gutman F; Aflalo-Hazan V; Kerrou K; Montravers F; Grahek D; Talbot JN
AJR Am J Roentgenol; 2006 Dec; 187(6):W618-21. PubMed ID: 17114515
[No Abstract] [Full Text] [Related]
11. Incidental detection of Hürthle cell adenoma by 18F-choline PET/CT scan in a patient with prostate cancer.
Paone G; Treglia G; Bongiovanni M; Ruberto T; Ceriani L; Giovanella L
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):340-1. PubMed ID: 23796426
[No Abstract] [Full Text] [Related]
12. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
[TBL] [Abstract][Full Text] [Related]
13. Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies.
Nanni C; Pettinato C; Ambrosini V; Spinelli A; Trespidi S; Rubello D; Al-Nahhas A; Franchi R; Alavi A; Fanti S
Nucl Med Commun; 2007 Jul; 28(7):547-53. PubMed ID: 17538396
[TBL] [Abstract][Full Text] [Related]
14. Radiation dosimetry of 18F-fluorocholine PET/CT studies in prostate cancer patients.
Fabbri C; Galassi R; Moretti A; Sintuzzi E; Mautone V; Sarti G; Strigari L; Benassi M; Matteucci F
Phys Med; 2014 May; 30(3):346-51. PubMed ID: 24238928
[TBL] [Abstract][Full Text] [Related]
15. (18)F-Choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer.
Kwee SA; Coel MN; Ly BH; Lim J
Ann Nucl Med; 2009 Aug; 23(6):541-8. PubMed ID: 19529978
[TBL] [Abstract][Full Text] [Related]
16. Optimized protocol for (18)F-choline PET/CT in patients with biochemically relapsed prostate cancer: experiences on 250 consecutive cases.
Chondrogiannis S; Marzola MC; Grassetto G; Rampin L; Massaro A; Colletti PM; Rubello D
Clin Nucl Med; 2015 Jun; 40(6):e308-12. PubMed ID: 25742236
[TBL] [Abstract][Full Text] [Related]
17. Cancer imaging with fluorine-18-labeled choline derivatives.
Kwee SA; DeGrado TR; Talbot JN; Gutman F; Coel MN
Semin Nucl Med; 2007 Nov; 37(6):420-8. PubMed ID: 17920349
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.
DeGrado TR; Baldwin SW; Wang S; Orr MD; Liao RP; Friedman HS; Reiman R; Price DT; Coleman RE
J Nucl Med; 2001 Dec; 42(12):1805-14. PubMed ID: 11752077
[TBL] [Abstract][Full Text] [Related]
19. Colchicine must be stopped before imaging with [18F]-methylcholine PET/CT.
Roef MJ; van der Poel H; van der Laken CJ; Vogel WV
Nucl Med Commun; 2010 Dec; 31(12):1075-7. PubMed ID: 21089227
[TBL] [Abstract][Full Text] [Related]
20. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
